Media stories about Aerie Pharmaceuticals (NASDAQ:AERI) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.4844522111633 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- Aerie Pharmaceuticals, Inc. (AERI) Given a $69.00 Price Target at Cantor Fitzgerald (americanbankingnews.com)
- Analysts Expect Aerie Pharmaceuticals, Inc. (AERI) Will Post Earnings of -$0.67 Per Share (americanbankingnews.com)
- Aerie Pharmaceuticals’ (NASDAQ:AERI) Buy Rating Reaffirmed at Mizuho – Newburgh Gazette (newburghgazette.com)
- Aerie Pharmaceuticals, Inc. to Host Earnings Call – Digital Journal (digitaljournal.com)
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded up $0.40 during trading on Thursday, hitting $59.70. 337,211 shares of the stock were exchanged, compared to its average volume of 524,391. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a 1-year low of $35.20 and a 1-year high of $66.25.
AERI has been the subject of a number of research reports. Guggenheim initiated coverage on shares of Aerie Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $80.00 price target for the company. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Mizuho reaffirmed a “buy” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research report on Monday, October 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $62.00 price target on shares of Aerie Pharmaceuticals in a research report on Wednesday, October 11th. Finally, Cowen and Company reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Thursday, October 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company. Aerie Pharmaceuticals has an average rating of “Buy” and an average target price of $71.43.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/11/16/aerie-pharmaceuticals-aeri-receives-daily-news-impact-rating-of-0-20.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.